The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

Robert F. Kennedy Jr., nominated to be health secretary, seemed unfamiliar with the particulars of the massive insurance ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Pharmaceutical executives are near unanimous (with 68% strongly agreeing and 31% somewhat agreeing) in their concern about a marked increase in theft, fraud, and/or attacks in the pharmaceutical ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...